Literature DB >> 32144841

Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.

Dominika A Kalkowska1, Kimberly M Thompson1.   

Abstract

Many countries use supplemental immunization activities (SIAs) with oral poliovirus vaccine (OPV) to keep their population immunity to transmission high using preventive, planned SIAs (pSIAs) and outbreaks response SIAs (oSIAs). Prior studies suggested that investment in pSIAs saved substantial health and financial costs due to avoided outbreaks. However, questions remain about the benefits of SIAs, particularly with the recent introduction of inactivated poliovirus vaccine (IPV) into routine immunization in all OPV-using countries. The mounting costs of polio eradication activities and the need to respond to oSIAs threatens the use of limited financial resources for pSIAs, including in the remaining countries with endemic transmission of serotype 1 wild poliovirus (WPV1) (i.e., Pakistan and Afghanistan). A recent updated global poliovirus transmission model suggested that the Global Polio Eradication Initiative (GPEI) is not on track to stop transmission of WPV1 in Pakistan and Afghanistan. We use the updated global model to explore the role of pSIAs to achieve WPV1 eradication. We find that unless Pakistan and Afghanistan manage to increase the quality of bivalent OPV (bOPV) pSIAs, which we model as intensity (i.e., sufficiently high-coverage bOPV pSIAs that reach missed children), the model does not lead to successful eradication of WPV1. Achieving WPV1 eradication, the global objectives of the GPEI, and a successful polio endgame depend on effective and sufficient use of OPV. IPV use plays a negligible role in stopping transmission in Pakistan and Afghanistan and most other countries supported by the GPEI, and more IPV use will not help to stop transmission.
© 2020 Society for Risk Analysis.

Entities:  

Keywords:  Dynamic modeling; eradication; oral poliovirus vaccine; polio

Mesh:

Substances:

Year:  2020        PMID: 32144841      PMCID: PMC7821345          DOI: 10.1111/risa.13471

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  18 in total

1.  Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Derek T Ehrhardt; Noha H Farag; Stephen C Hadler; Lee M Hampton; Maureen Martinez; Steve G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-01-03       Impact factor: 4.000

2.  Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

3.  Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-09-21       Impact factor: 4.000

4.  Modeling population immunity to support efforts to end the transmission of live polioviruses.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Stephen L Cochi
Journal:  Risk Anal       Date:  2012-09-17       Impact factor: 4.000

5.  Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Steven G F Wassilak; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  J Vaccines Vaccin       Date:  2016-10-03

Review 6.  Eradication versus control for poliomyelitis: an economic analysis.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Lancet       Date:  2007-04-21       Impact factor: 79.321

7.  The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting.

Authors:  Tara D Mangal; R Bruce Aylward; Nicholas C Grassly
Journal:  Am J Epidemiol       Date:  2013-10-07       Impact factor: 4.897

8.  Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.

Authors:  Lee M Hampton; Gaël Maufras du Châtellier; Jacqueline Fournier-Caruana; Ann Ottosen; Jennifer Rubin; Lisa Menning; Margaret Farrell; Stephanie Shendale; Manish Patel
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

Review 9.  Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

10.  Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-01-20       Impact factor: 4.000

View more
  6 in total

Review 1.  Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Stephanie D Kovacs; Steven G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-07-06       Impact factor: 4.000

2.  Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2021-02       Impact factor: 4.000

3.  Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Amanda Wilkinson; Ananda S Bandyopadhyay; Jennifer L Konopka-Anstadt; Cara C Burns; M Steven Oberste; Steven G F Wassilak; Kamran Badizadegan; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-11-10       Impact factor: 4.000

4.  Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019-2023.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835

Review 5.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

6.  Potential Future Use, Costs, and Value of Poliovirus Vaccines.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-07-09       Impact factor: 4.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.